Peroxisome proliferator-activated receptor γ in human breast carcinoma: A modulator of estrogenic actions

Endocrine-Related Cancer

Volumn 13, Issue 1, 2006, Pages 233-250

  Suzuki, T ^a   Hayashi, S ^a   Miki, Y ^a   Nakamura, Y ^a   Moriya, T ^a   Sugawara, A ^a   Ishida, T ^a   Ohuchi, N ^a   Sasano, H ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 2 CHLORO 5 NITROBENZANILIDE; ANTIBODY; CYCLOOXYGENASE 2; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; PROGESTERONE RECEPTOR; PROTEIN P21; PROTEIN P27; RETINOID X RECEPTOR;

ADULT; AGED; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CARCINOMA CELL; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG INHIBITION; ESTROGEN ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOLOCALIZATION; IMMUNOREACTIVITY; MICROARRAY ANALYSIS; MULTIVARIATE ANALYSIS; NUCLEOTIDE SEQUENCE; REAL TIME POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS; UNINDEXED SEQUENCE; UNIVARIATE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; BIOLOGICAL RESPONSE MODIFIERS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL PROLIFERATION; CHEMOTHERAPY, ADJUVANT; CYCLIN-DEPENDENT KINASE INHIBITOR P21; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PPAR GAMMA; PROSTAGLANDIN D2; RECEPTORS, ESTROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANS-ACTIVATION (GENETICS); TUMOR CELLS, CULTURED;

EID: 33645974281     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.1.01075     Document Type: Article

References (61)

1. Acconcia F & Marino M 2003 Synergism between genomic and non genomic estrogen action mechanisms. IUBMB Life 55 145-150.
2. Allred DC, Harvey JM, Berardo M & Clark GM 1998 Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Modern Pathology 11 155-168.
3. Badawi AF & Badr MZ 2003 Expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-gamma and levels of prostaglandin E2 and 15-deoxy-delta12,14-prostaglandin J2 in human breast cancer and metastasis. International Journal of Cancer 103 84-90.
4. Barak Y, Nelson MC, Ong ES, Jones YZ, Ruiz-Lozano P, Chien KR, Koder A & Evans RM 1999 PPAR gamma is required for placental, cardiac, and adipose tissue development. Molecular Cell 4 585-595.
5. Barbareschi M, Pelosio P, Caffo O, Buttitta F, Pellegrini S, Barbazza R, Dalla Palma P, Bevilacqua G & Marchetti A 1997 Cyclin-D1-gene amplification and expression in breast carcinoma: relation with clinicopathologic characteristics and with retinoblastoma gene product, p53 and p21WAF1 immunohistochemical expression. International Journal of Cancer 74 171-174.
6. Barbareschi M, van Tinteren H, Mauri FA, Veronese S, Peterse H, Maisonneuve P, Caffo O, Scaioli M, Doglioni C, Galligioni E et al. 2000 p27 (kip1) expression in breast carcinomas: an immunohistochemical study on 512 patients with long-term follow-up. International Journal of Cancer 89 236-241.
7. Bourdeau V, Deschenes J, Metivier R, Nagai Y, Nguyen D, Bretschneider N, Gannon F, White JH & Mader S 2004 Genome-wide identification of high-affinity estrogen response elements in human and mouse. Molecular Endocrinology 18 1411-1427.
8. Burstein HJ, Demetri GD, Mueller E, Sarraf P, Spiegelman BM & Winer EP 2003 Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Research and Treatment 79 391-397.
9. Celi FS & Shuldiner AR 2002 The role of peroxisome proliferator-activated receptor gamma in diabetes and obesity. Current Diabetes Reports 2 179-185.
10. Chung SH, Onoda N, Ishikawa T, Ogisawa K, Takenaka C, Yano Y, Hato F & Hirakawa K 2002 Peroxisome proliferator-activated receptor gamma activation induces cell cycle arrest via the p53-independent pathway in human anaplastic thyroid cancer cells. Japanese Journal of Cancer Research 93 1358-1365.
11. Colombel M, Dante R, Bouvier R, Ribieras S, Pangaud C, Marechal JM & Lasne Y 1999 Differential RNA expression of the pS2 gene in the human benign and malignant prostatic tissue. Journal of Urology 162 927-930.
12. Crowe DL & Chandraratna RA 2004 A retinoid X receptor (RXR)-selective retinoid reveals that RXR-alpha is potentially a therapeutic target in breast cancer cell lines, and that it potentiates antiproliferative and apoptotic responses to peroxisome proliferator-activated receptor ligands. Breast Cancer Research 6 R546-R555.
13. Dowlatshahi K, Fan M, Snider HC & Habib FA 1997 Lymph node micrometastases from breast carcinoma: reviewing the dilemma. Cancer 80 1188-1197.
14. Dumoulin FL, Nischalke HD, Leifeld L, von dem Bussche A, Rockstroh JK, Sauerbruch T & Spengler U 2000 Semi-quantification of human C-C chemokine mRNAs with reverse transcription/real-time PCR using multi-specific standards. Journal of Immunological Methods 241 109-119.
15. Elstner E, Muller C, Koshizuka K, Williamson EA, Park D, Asou H, Shintaku P, Said JW, Heber D & Koeffler HP 1998 Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. PNAS 95 8806-8811.
16. Elston CW & Ellis IO 1991 Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer. Experience from a large study with long-term follow-up. Histopathology 19 403-410.
17. Gavrieli Y, Sherman Y & Ben-Sasson SA 1992 Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. Journal of Cell Biology 119 493-501.
18. Gillesby BE & Zacharewski TR 1999 pS2 (TFF1) levels in human breast cancer tumor samples: correlation with clinical and histological prognostic markers. Breast Cancer Research and Treatment 56 253-265.
19. Ham EA, Cirillo VJ, Zanetti ME & Kuehl FA Jr 1975 Estrogen-directed synthesis of specific prostaglandins in uterus. PNAS 72 1420-1424.
20. Han S, Sidell N, Fisher PB & Roman J 2004 Up-regulation of p21 gene expression by peroxisome proliferator-activated receptor gamma in human lung carcinoma cells. Clinical Cancer Research 10 1911-1919.
21. Hayashi SI, Eguchi H, Tanimoto K, Yoshida T, Omoto Y, Inoue A, Yoshida N & Yamaguchi Y 2003 The expression and function of estrogen receptor alpha and beta in human breast cancer and its clinical application. Endocrine-Related Cancer 10 193-202.
22. Horwitz KB & McGuire WL 1978 Estrogen control of progesterone receptor in human breast cancer. Correlation with nuclear processing of estrogen receptor. Journal of Biological Chemistry 253 2223-2228.
23. Inoue A, Yoshida N, Omoto Y, Oguchi S, Yamori T, Kiyama R & Hayashi S 2002 Development of cDNA microarray for expression profiling of estrogen-responsive genes. Journal of Molecular Endocrinology 29 175-192.
24. Ioachim E, Tsanou E, Briasoulis E, Batsis C, Karavasilis V, Charchanti A, Pavlidis N & Agnantis NJ 2003 Clinicopathological study of the expression of hsp27, pS2, cathepsin D and metallothionein in primary invasive breast cancer. Breast 12 111-119.
25. Isobe I, Michikawa M & Yanagisawa K 1999 Enhancement of MTT, a tetrazolium salt, exocytosis by amyloid beta-protein and chloroquine in cultured rat astrocytes. Neuroscience Letters 266 129-132.
26. Jiang WG, Douglas-Jones A & Mansel RE 2003 Expression of peroxisome-proliferator activated receptor-gamma (PPARgamma) and the PPARgamma co-activator, PGC-1, in human breast cancer correlates with clinical outcomes. International Journal of Cancer 106 752-757.
27. Kao YR, Shih JY, Wen WC, Ko YP, Chen BM, Chan YL, Chu YW, Yang PC, Wu CW & Roffler SR 2003 Tumor-associated antigen L6 and the invasion of human lung cancer cells. Clinical Cancer Research 9 2807-2816.
28. Keller H, Givel F, Perroud M & Wahli W 1995 Signaling cross-talk between peroxisome proliferator-activated receptor/retinoid X receptor and estrogen receptor through estrogen response elements. Molecular Endocrinology 9 794-804.
29. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC & Lehmann JM 1995 A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 83 813-819.
30. Koeffler HP 2003 Peroxisome proliferator-activated receptor gamma and cancers. Clinical Cancer Research 9 1-9.
31. Korach KS 1994 Insights from the study of animals lacking functional estrogen receptor. Science 266 1524-1527.
32. Kumar V, Green S, Stack G, Berry M, Jin JR & Chambon P 1987 Functional domains of the human estrogen receptor. Cell 51 941-951.
33. Lapillonne H, Konopleva M, Tsao T, Gold D, McQueen T, Sutherland RL, Madden T & Andreeff M 2003 Activation of peroxisome proliferator-activated receptor gamma by a novel synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest and apoptosis in breast cancer cells. Cancer Research 63 5926-5939.
34. Leesnitzer LM, Parks DJ, Bledsoe RK, Cobb JE, Collins JL, Consler TG, Davis RG, Hull-Ryde EA, Lenhard JM, Patel L et al. 2002 Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry 41 6640-6650.
35. Lemberger T, Desvergne B & Wahli W 1996 Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. Annual Review of Cell and Developmental Biology 12 335-363.
36. Ma H, Sprecher HW & Kolattukudy PE 1998a Estrogen-induced production of a peroxisome proliferator-activated receptor (PPAR) ligand in a PPARgamma-expressing tissue. Journal of Biological Chemistry 273 30131-30138.
37. Ma H, Tam QT & Kolattukudy PE 1998a Peroxisome proliferator-activated receptor gamma 1 (PPAR-gamma1) as a major PPAR in a tissue in which estrogen induces peroxisome proliferation. FEBS Letters 434 394-400.
38. Mangelsdorf DJ & Evans RM 1995 The RXR heterodimers and orphan receptors. Cell 83 841-850.
39. Motomura W, Takahashi N, Nagamine M, Sawamukai M, Tanno S, Kohgo Y & Okumura T 2004 Growth arrest by troglitazone is mediated by p27Kip1 accumulation, which results from dual inhibition of proteasome activity and Skp2 expression in human hepatocellular carcinoma cells. International Journal of Cancer 108 41-46.
40. Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, Fletcher C, Singer S & Spiegelman BM 1998 Terminal differentiation of human breast cancer through PPAR gamma. Molecular Cell 1 465-470.
41. O'Lone R, Frith MC, Karlsson EK & Hansen U 2004 Genomic targets of nuclear estrogen receptors. Molecular Endocrinology 18 1859-1875.
42. Paruthiyil S, Parmar H, Kerekatte V, Cunha GR, Firestone GL & Leitman DC 2004 Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Research 64 423-428.
43. Pellikainen MJ, Pekola TT, Ropponen KM, Kataja W, Kellokoski JK, Eskelinen MJ & Kosma VM 2003 p21WAF1 expression in invasive breast cancer and its association with p53, AP-2, cell proliferation, and prognosis. Journal of Clinical Pathology 56 214-220.
44. Qin C, Singh P & Safe S 1999 Transcriptional activation of insulin-like growth factor-binding protein-4 by 17beta-estradiol in MCF-7 cells: role of estrogen receptor-Sp1 complexes. Endocrinology 140 2501-2508.
45. Qin C, Burghardt R, Smith R, Wormke M, Stewart J & Safe S 2003 Peroxisome proliferator-activated receptor gamma agonists induce proteasome-dependent degradation of cyclin D1 and estrogen receptor alpha in MCF-7 breast cancer cells. Cancer Research 63 958-964.
46. Saji S, Okumura N, Eguchi H, Nakashima S, Suzuki A, Toi M, Nozawa Y, Saji S & Hayashi S 2001 MDM2 enhances the function of estrogen receptor alpha in human breast cancer cells. Biochemical and Biophysical Research Communications 281 259-265.
47. Sakamoto T, Eguchi H, Omoto Y, Ayabe T, Mori H & Hayashi S 2002 Estrogen receptor-mediated effects of tamoxifen on human endometrial cancer cells. Molecular and Cellular Endocrinology 192 93-104.
48. Sato K, Sugawara A, Kudo M, Uruno A, Ito S & Takeuchi K 2004 Expression of peroxisome proliferator-activated receptor isoform proteins in the rat kidney. Hypertension Research 27 417-425.
49. Schonherr E, Levkau B, Schaefer L, Kresse H & Walsh K 2001 Decorin-mediated signal transduction in endothelial cells. Involvement of Akt/protein kinase B in up-regulation of p21(WAF1/CIP1) but not p27(KIP1). Journal of Biological Chemistry 276 40687-40692.
50. Schoonjans K, Staels B & Auwerx J 1996 Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. Journal of Lipid Research 37 907-925.
51. Stack G, Kumar V, Green S, Ponglikitmongkol M, Berry M, Rio MC, Nunez AM, Roberts M, Koehl C, Bellocq P et al. 1988 Structure and function of the pS2 gene and estrogen receptor in human breast cancer cells. Cancer Treatment and Research 40 185-206.
52. Sugawara A, Yen PM, Qi Y, Lechan RM & Chin WW 1995 Isoform-specific retinoid-X receptor (RXR) antibodies detect differential expression of RXR proteins in the pituitary gland. Endocrinology 136 1766-1774.
53. Suzuki T, Moriya T, Sugawara A, Ariga N, Takabayashi H & Sasano H 2001 Retinoid receptors in human breast carcinoma: possible modulators of in situ estrogen metabolism. Breast Cancer Research and Treatment 65 31-40.
54. Tontonoz P, Hu E, Graves RA, Budavari AI & Spiegelman BM 1994 mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes and Development 8 1224-1234.
55. Tsai MJ & O'Malley BW 1994 Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annual Review of Biochemistry 63 451-486.
56. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A & Speleman, F 2002 Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biology 3 research0034.1-0034.11
57. Wang F, Porter W, Xing W, Archer TK & Safe S 1997 Identification of a functional imperfect estrogen-responsive element in the 5′-promoter region of the human cathepsin D gene. Biochemistry 36 7793-7801.
58. Wang X, Southard RC & Kilgore MW 2004 The increased expression of peroxisome proliferator-activated receptor-gamma1 in human breast cancer is mediated by selective promoter usage. Cancer Research 64 5592-5596.
59. Watkins G, Douglas-Jones A, Mansel RE & Jiang WG 2004 The localisation and reduction of nuclear staining of PPARgamma and PGC-1 in human breast cancer. Oncology Reports 12 483-488.
60. Yee LD, Sabourin CL, Liu L, Li HM, Smith PJ, Seewaldt V & Kniss DA 1999 Peroxisome proliferator-activated receptor gamma activation in human breast cancer. International Journal of Oncology 15 967-973.
61. Yoshida N, Omoto Y, Inoue A, Eguchi H, Kobayashi Y, Kurosumi M, Saji S, Suemasu K, Okazaki T, Nakachi K et al. 2004 Prediction of prognosis of estrogen receptor-positive breast cancer with combination of selected estrogen-regulated genes. Cancer Science 95 496-502.